Total Payments
$901,128
2024 Payments
$108,138
Companies
45
Transactions
1,216
Medicare Patients
718
Medicare Billing
$50,997
Payment Breakdown by Category
Other$640,082 (71.0%)
Consulting$154,989 (17.2%)
Travel$76,743 (8.5%)
Food & Beverage$25,015 (2.8%)
Research$2,835 (0.3%)
Gifts$1,079 (0.1%)
Education$385.57 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $640,082 | 241 | 71.0% |
| Consulting Fee | $154,989 | 44 | 17.2% |
| Travel and Lodging | $76,743 | 185 | 8.5% |
| Food and Beverage | $25,015 | 728 | 2.8% |
| Unspecified | $2,835 | 8 | 0.3% |
| Gift | $1,079 | 4 | 0.1% |
| Education | $385.57 | 6 | 0.0% |
Payments by Type
General
$898,293
1,208 transactions
Research
$2,835
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $351,824 | 355 | $0 (2024) |
| EMD Serono, Inc. | $149,330 | 138 | $0 (2024) |
| Biogen, Inc. | $146,867 | 246 | $0 (2024) |
| Genentech USA, Inc. | $107,643 | 85 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $49,955 | 145 | $0 (2024) |
| TG Therapeutics, Inc. | $43,555 | 47 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $22,396 | 16 | $0 (2022) |
| Celgene Corporation | $17,859 | 47 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,918 | 3 | $0 (2018) |
| F. Hoffmann-La Roche AG | $2,029 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $108,138 | 105 | GENZYME CORPORATION ($36,065) |
| 2023 | $115,237 | 165 | EMD Serono, Inc. ($51,393) |
| 2022 | $92,545 | 131 | EMD Serono, Inc. ($35,748) |
| 2021 | $68,874 | 92 | Biogen, Inc. ($18,463) |
| 2020 | $63,273 | 95 | EMD Serono, Inc. ($19,072) |
| 2019 | $175,993 | 251 | GENZYME CORPORATION ($92,889) |
| 2018 | $192,363 | 270 | GENZYME CORPORATION ($131,482) |
| 2017 | $84,705 | 107 | GENZYME CORPORATION ($59,553) |
All Payment Transactions
1,216 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,175.00 | General |
| Category: Neurology | ||||||
| 12/11/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,894.00 | General |
| 12/10/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,894.00 | General |
| 12/09/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,038.00 | General |
| 12/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $890.90 | General |
| 12/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $684.33 | General |
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $87.63 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Neurology | ||||||
| 11/05/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.15 | General |
| 10/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.33 | General |
| Category: Neuroscience | ||||||
| 10/08/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Neurology | ||||||
| 10/01/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Neurology | ||||||
| 10/01/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/24/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,466.00 | General |
| 09/24/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $50.31 | General |
| 09/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $63.17 | General |
| 09/18/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,347.00 | General |
| Category: Neurology | ||||||
| 09/18/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $119.00 | General |
| Category: Immunology | ||||||
| 09/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $76.47 | General |
| Category: Immunology | ||||||
| 09/13/2024 | Biogen, Inc. | VUMERITY (Drug) | Consulting Fee | Cash or cash equivalent | $449.00 | General |
| Category: Neurology | ||||||
| 09/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,143.00 | General |
| Category: Neurology | ||||||
| 09/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $71.63 | General |
| Category: Neurology | ||||||
| 09/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Neurology | ||||||
| 08/22/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,038.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Satralizumab Treatment in Adults With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series | F. Hoffmann-La Roche AG | $2,029 | 1 |
| M14-398 & M14-397 | AbbVie, Inc. | $545.83 | 6 |
| MS700568-0079 | EMD Serono, Inc. | $261.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 135 | 219 | $36,709 | $12,732 |
| 2022 | 3 | 174 | 212 | $31,578 | $13,707 |
| 2021 | 7 | 227 | 261 | $30,975 | $14,794 |
| 2020 | 6 | 182 | 212 | $24,396 | $9,765 |
Total Patients
718
Total Services
904
Medicare Billing
$50,997
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 100 | 165 | $24,235 | $10,465 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 54 | $12,474 | $2,267 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 116 | 151 | $21,392 | $10,250 | 47.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 15 | $2,834 | $1,402 | 49.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 22 | $5,096 | $1,052 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 24 | 24 | $2,256 | $1,002 | 44.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 58 | 67 | $9,760 | $5,217 | 53.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 69 | 87 | $8,432 | $3,987 | 47.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 14 | 15 | $2,835 | $1,706 | 60.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 29 | 29 | $4,134 | $1,451 | 35.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 28 | 32 | $3,134 | $1,343 | 42.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 11 | $1,540 | $601.87 | 39.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 18 | 20 | $1,140 | $487.90 | 42.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 59 | $8,512 | $3,067 | 36.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 56 | 66 | $6,170 | $2,275 | 36.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 17 | $3,213 | $1,531 | 47.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 33 | 40 | $2,905 | $1,500 | 51.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $2,568 | $1,184 | 46.1% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 18 | 18 | $1,028 | $209.30 | 20.4% |
About Dr. Robert Pace, MD
Dr. Robert Pace, MD is a Neurology healthcare provider based in Owosso, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1144483660.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Pace, MD has received a total of $901,128 in payments from pharmaceutical and medical device companies, with $108,138 received in 2024. These payments were reported across 1,216 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($640,082).
As a Medicare-enrolled provider, Pace has provided services to 718 Medicare beneficiaries, totaling 904 services with total Medicare billing of $50,997. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Owosso, MI
- Active Since 07/03/2008
- Last Updated 11/26/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1144483660
Products in Payments
- LEMTRADA (Drug) $210,184
- Mavenclad (Drug) $88,274
- AUBAGIO (Drug) $87,656
- OCREVUS (Biological) $84,259
- TYSABRI (Biological) $68,597
- ZEPOSIA (Drug) $40,105
- BRIUMVI (Drug) $38,748
- TECFIDERA (Drug) $30,711
- MAVENCLAD (Drug) $22,478
- VUMERITY (Drug) $20,812
- Ocrevus (Biological) $20,691
- GILENYA (Drug) $11,116
- KESIMPTA (Drug) $9,353
- NO PRODUCT DISCUSSED (Drug) $9,225
- MAYZENT (Drug) $8,585
- Betaseron (Drug) $4,918
- Tysabri (Biological) $2,856
- Enspryng (Biological) $2,061
- PLEGRIDY (Biological) $1,850
- Mavenclad (Biological) $291.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Owosso
Dr. Rany Aburashed, D.o, D.O
Neurology — Payments: $1.2M
Neurology $1.2M
Margaret Frey, Do, DO
Neurology — Payments: $409,351
Neurology $409,351
Rosemarie Walch, Do, DO
Neurology — Payments: $400,076
Neurology $400,076
Cara Leahy, Do, DO
Neurology — Payments: $115,077
Neurology $115,077
Anthony Brune, Do, DO
Neurology — Payments: $18,437
Neurology $18,437
Dustin Nowacek, Md, MD
Neurology — Payments: $8,682
Neurology $8,682